Xi Zhang1, Yu-Ge Ran1, Kun-Jie Wang2. 1. Department of Radiation Oncology, Affiliated Hospital of Hebei University, Baoding 071000, China. 2. Department of Medical Oncology, Affiliated Hospital of Hebei University, Baoding 071000, China.
Abstract
BACKGROUND: A meta-analysis of randomized controlled trials was performed to determine the overall risk of noninfectious severe pneumonitis associated with mTOR inhibitors (mTORi) in cancer patients. MATERIALS & METHODS: PubMed, EMBASE and oncology conference proceedings were searched for relevant studies. RESULTS: A total of 8377 patients from 16 randomized controlled trials were included. The incidence of severe pneumonitis associated with mTORi was 1.7% (95% CI: 1.1-2.5%). The use of mTORi significantly increased the risk of severe pneumonitis compared with controls (odds ratio: 3.36; 95% CI: 2.20-5.12). The analysis was stratified for drug types, tumor types, controlled therapy and mTORi-based regimens, but no significant differences in odds ratios were observed. CONCLUSION: mTORi significantly increase the risk of severe pneumonitis in cancer patients.
BACKGROUND: A meta-analysis of randomized controlled trials was performed to determine the overall risk of noninfectious severe pneumonitis associated with mTOR inhibitors (mTORi) in cancerpatients. MATERIALS & METHODS: PubMed, EMBASE and oncology conference proceedings were searched for relevant studies. RESULTS: A total of 8377 patients from 16 randomized controlled trials were included. The incidence of severe pneumonitis associated with mTORi was 1.7% (95% CI: 1.1-2.5%). The use of mTORi significantly increased the risk of severe pneumonitis compared with controls (odds ratio: 3.36; 95% CI: 2.20-5.12). The analysis was stratified for drug types, tumor types, controlled therapy and mTORi-based regimens, but no significant differences in odds ratios were observed. CONCLUSION: mTORi significantly increase the risk of severe pneumonitis in cancerpatients.
Authors: Ajay Major; Justin Kline; Theodore G Karrison; Paul A S Fishkin; Amy S Kimball; Adam M Petrich; Sreenivasa Nattam; Krishna Rao; Bethany G Sleckman; Kenneth Cohen; Koen van Besien; Aaron P Rapoport; Sonali M Smith Journal: Haematologica Date: 2022-07-01 Impact factor: 11.047